Systematic review of brain and blood lipidomics in Alzheimer's disease mouse models

Prog Lipid Res. 2023 Apr:90:101223. doi: 10.1016/j.plipres.2023.101223. Epub 2023 Mar 5.

Abstract

Alzheimer's disease (AD) diagnosis is based on invasive and expensive biomarkers. Regarding AD pathophysiological mechanisms, there is evidence of a link between AD and aberrant lipid homeostasis. Alterations in lipid composition have been observed in blood and brain samples, and transgenic mouse models represent a promising approach. Nevertheless, there is great variability among studies in mice for the determination of different types of lipids in targeted and untargeted methods. It could be explained by the different variables (model, age, sex, analytical technique), and experimental conditions used. The aim of this work is to review the studies on lipid alteration in brain tissue and blood samples from AD mouse models, focusing on different experimental parameters. As result, great disparity has been observed among the reviewed studies. Brain studies showed an increase in gangliosides, sphingomyelins, lysophospholipids and monounsaturated fatty acids and a decrease in sulfatides. In contrast, blood studies showed an increase in phosphoglycerides, sterols, diacylglycerols, triacylglycerols and polyunsaturated fatty acids, and a decrease in phospholipids, lysophospholipids and monounsaturated fatty acids. Thus, lipids are closely related to AD, and a consensus on lipidomics studies could be used as a diagnostic tool and providing insight into the mechanisms involved in AD.

Keywords: Alzheimer's disease; Brain; Lipidomics; Lipids; Mouse model; Plasma.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Alzheimer Disease*
  • Animals
  • Brain
  • Fatty Acids, Monounsaturated
  • Lipidomics / methods
  • Lysophospholipids
  • Mice
  • Mice, Transgenic

Substances

  • Fatty Acids, Monounsaturated
  • Lysophospholipids